A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: Deep vein thrombosis

  • DVT and PE: How Long to Treat With Anticoagulants?

    Explanation for Patients The complex topic of “Length of Anticoagulant Treatment” for patients with VTE  is being addressed in a blog entry written for patients, found on the Clot Connect patient education blog (here). For the Health Care Professional Well respected treatment guidelines exist [ref 1,2].

  • DVT and PE: How Long to Treat with “Blood Thinners”

    What Kind of Clot did You Have? If you have had a blood clot in your legs or your lung (pulmonary embolism=PE), you will wonder how long you should stay on a “blood thinner”. The decision depends on a number of factors which will be discussed below.

  • Apixaban (Eliquis®) – Another New Oral Anticoagulant

    Good news.  Another one of the new oral anticoagulants in development,  Apixaban (Eliquis®), has moved forward.  On May 20th, 2011, the European Medicines Agency (EMA) approved Eliquis® for DVT prevention after orthopedic surgery (hip and knee replacement) in the 27 countries of the European Community. In the U.S., however, Eliquis® is still some way away from getting FDA approval

  • What Causes Clots? – A Family Study

    Background It is known that the risk for blood clots in the leg (DVT) and lung (PE) is partly inherited. Some genes that increase the risk for DVT and PE are known (e.g. factor V Leiden, the factor II 20210 mutation, protein, protein C, S and antithrombin mutations). However, it is suspected that many other and,…

  • Athletes and DVT + PE

    Background Many people think of DVT and PE as a problem occurring in elderly people, but not in young and apparently healthy individuals. While it is certainly true that they occur more commonly in the elderly and in non-athletic overweight individuals, they can, nevertheless, happen in young, normal weight, and athletic people.

  • Athletes and Blood Clots

    Many people think of blood clots as a problem occurring in elderly people, but not in young and apparently healthy individuals. While it is true that clots occur more commonly in the elderly and in non-athletic overweight individuals, they can, nevertheless, happen in young, normal weight, and athletic people.

  • Testosterone and Thrombosis

    Testosterone Replacement Therapy Replacement therapy with low doses of testosterone does not adversely affect blood coagulation status [ref 1] and does not appear to increase the risk of venous or arterial thrombosis. Thrombosis is not listed as a potential side effect in the commly used drug compendium (Micromedex). Furthermore, the 2006 “Clinical Practice Guideline” from the…

  • Testosterone and Blood Clots

    Testosterone Replacement Therapy Replacement therapy with low doses of testosterone does not adversely affect blood coagulation status [ref 1] and does not appear to increase the risk of venous or arterial blood clots. Thrombosis is not listed as a potential side effect in a commly used drug compendium (Micromedex). Furthermore, the 2006 “Clinical Practice Guideline”…